Literature DB >> 33510592

Going, Toll-like receptors in skin inflammation and inflammatory diseases.

Vijay Kumar1,2.   

Abstract

The Indian Ayurvedic physicians knew the concept of inflammation dating back to 1500 BC. The continuous progress in the immunology of inflammation has explained its undiscovered mechanisms. For example, the discovery of Toll-like receptor 4 (TLR4) in humans (1997) has revolutionized the field of infection biology and innate immunity. The laboratory mice have shown twelve TLRs and express TLR10 (CD290) as a disrupted pseudogene, and humans have ten functional TLRs. Now, it is well established that TLRs play a significant role in different infectious and inflammatory diseases. Skin inflammation and other associated inflammatory diseases, including atopic dermatitis (AD), acne vulgaris, and psoriasis, along with many skin cancers are major health problems all over the world. The continuous development in the immunopathogenesis of inflammatory skin diseases has opened the window of opportunity for TLRs in studying their role. Hence, the manuscript explores the role of different TLRs in the pathogenesis of skin inflammation and associated inflammatory diseases. The article starts with the concept of inflammation, its origin, and the impact of TLRs discovery on infection and inflammation biology. The subsequent section describes the burden of skin-associated inflammatory diseases worldwide and the effect of the geographical habitat of people affecting it. The third section explains skin as an immune organ and explains the expression of different TLRs on different skin cells, including keratinocytes, Langerhans cells (LCs), skin fibroblasts, and melanocytes. The fourth section describes the impact of TLRs on these cells in different skin-inflammatory conditions, including acne vulgaris, AD, psoriasis, and skin cancers. The article also discusses the use of different TLR-based therapeutic approaches as specific to these inflammatory skin diseases.
Copyright © 2021 Kumar.

Entities:  

Keywords:  TLRs; atopic dermatitis; inflammation; melanoma; psoriasis; skin

Year:  2021        PMID: 33510592      PMCID: PMC7838829          DOI: 10.17179/excli2020-3114

Source DB:  PubMed          Journal:  EXCLI J        ISSN: 1611-2156            Impact factor:   4.068


  225 in total

1.  TLR expression in human melanoma cells.

Authors:  Mélanie Saint-Jean; Anne-Chantal Knol; Jean-Michel Nguyen; Amir Khammari; Brigitte Dréno
Journal:  Eur J Dermatol       Date:  2011 Nov-Dec       Impact factor: 3.328

2.  Icariside II potentiates paclitaxel-induced apoptosis in human melanoma A375 cells by inhibiting TLR4 signaling pathway.

Authors:  Jinfeng Wu; Ming Guan; Pok Fai Wong; Howard Yu; Jingcheng Dong; Jinhua Xu
Journal:  Food Chem Toxicol       Date:  2012-06-26       Impact factor: 6.023

Review 3.  The role of ubiquitylation in immune defence and pathogen evasion.

Authors:  Xiaomo Jiang; Zhijian J Chen
Journal:  Nat Rev Immunol       Date:  2011-12-09       Impact factor: 53.106

4.  Health Care Utilization, Patient Costs, and Access to Care in US Adults With Eczema: A Population-Based Study.

Authors:  Jonathan I Silverberg
Journal:  JAMA Dermatol       Date:  2015-07       Impact factor: 10.282

Review 5.  Emerging Skin T-Cell Functions in Response to Environmental Insults.

Authors:  Jutamas Suwanpradid; Zachary E Holcomb; Amanda S MacLeod
Journal:  J Invest Dermatol       Date:  2016-10-23       Impact factor: 8.551

6.  Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide.

Authors:  Roberto Lande; Josh Gregorio; Valeria Facchinetti; Bithi Chatterjee; Yi-Hong Wang; Bernhard Homey; Wei Cao; Yui-Hsi Wang; Bing Su; Frank O Nestle; Tomasz Zal; Ira Mellman; Jens-Michael Schröder; Yong-Jun Liu; Michel Gilliet
Journal:  Nature       Date:  2007-09-16       Impact factor: 49.962

7.  Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery.

Authors:  Lindy L Thomsen; Peter Topley; Maria G Daly; Sara J Brett; John P Tite
Journal:  Vaccine       Date:  2004-04-16       Impact factor: 3.641

Review 8.  Resolution of inflammation: state of the art, definitions and terms.

Authors:  Charles N Serhan; Sue D Brain; Christopher D Buckley; Derek W Gilroy; Christopher Haslett; Luke A J O'Neill; Mauro Perretti; Adriano G Rossi; John L Wallace
Journal:  FASEB J       Date:  2007-02       Impact factor: 5.191

9.  The significance of Toll-like receptor (TLR) 2 and 9 gene polymorphisms in psoriasis.

Authors:  Monika Zabłotna; Michał Sobjanek; Dorota Purzycka-Bohdan; Aneta Szczerkowska-Dobosz; Bogusław Nedoszytko; Roman J Nowicki
Journal:  Postepy Dermatol Alergol       Date:  2017-02-07       Impact factor: 1.837

10.  The αC helix of TIRAP holds therapeutic potential in TLR-mediated autoimmune diseases.

Authors:  Masaud Shah; Gi-Young Kim; Asma Achek; Eun-Young Cho; Wook-Young Baek; Yang Seon Choi; Wang Hee Lee; Dong-Jin Kim; Sang Ho Lee; Wook Kim; Soon Sun Kim; Jae Youn Cheong; Chang-Hee Suh; Sangdun Choi
Journal:  Biomaterials       Date:  2020-03-17       Impact factor: 12.479

View more
  4 in total

1.  TLR4 polymorphisms as potential predictors of atopic dermatitis in Chinese Han children.

Authors:  Jianrong Shi; Lin He; Ran Tao; Huiwen Zheng; Wei Li; Shuangshuang Huang; Yunling Li; Shiqiang Shang
Journal:  J Clin Lab Anal       Date:  2022-03-29       Impact factor: 3.124

Review 2.  Inflammatory Microenvironment of Skin Wounds.

Authors:  Zhen Wang; Fang Qi; Han Luo; Guangchao Xu; Dali Wang
Journal:  Front Immunol       Date:  2022-03-01       Impact factor: 7.561

Review 3.  Probiotic-Based Bacteriocin: Immunity Supplementation Against Viruses. An Updated Review.

Authors:  Muhammad Umair; Saqib Jabbar; Lu Zhaoxin; Zhang Jianhao; Muhammad Abid; Kashif-Ur R Khan; Sameh A Korma; Mashail A Alghamdi; Mohamed T El-Saadony; Mohamed E Abd El-Hack; Ilaria Cacciotti; Synan F AbuQamar; Khaled A El-Tarabily; Liqing Zhao
Journal:  Front Microbiol       Date:  2022-07-26       Impact factor: 6.064

4.  In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties.

Authors:  Eduardo Perez; Jose R Fernandez; Corey Fitzgerald; Karl Rouzard; Masanori Tamura; Christopher Savile
Journal:  Molecules       Date:  2022-01-13       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.